Overview Financials News + Filings Key Docs Ownership Insiders
|
In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 |
| 20-F | 20-F | 20-F | 20-F |
Revenues: |
US | | 0.0 | 0.0 | 0.3 |
Rest of the world | | 0.0 | 0.2 | 0.2 |
Israel | | | 0.0 | 0.0 |
Norway | | | 0.0 | 0.1 |
Other | | | 0.1 | 0.1 |
Total revenues | 0.0 | 0.0 | 0.4 | 0.7 |
Revenue growth [+] | -100.0% | -98.5% | -43.0% | |
US | | -81.5% | -91.7% | |
Rest of the world | | -99.5% | 17.9% | |
Israel | | | 16.7% | |
Norway | | | -16.7% | |
Germany | | | -18.0% | |
Cost of goods sold | 0.5 | 1.0 | 0.6 | 0.5 |
Gross profit | -0.5 | -1.0 | -0.3 | 0.2 |
Gross margin | | -16483.3% | -66.8% | 28.0% |
Selling, general and administrative | 49.2 | 262.1 | 38.3 | 7.2 |
Research and development | 78.2 | 252.4 | 29.6 | 7.0 |
Other operating expenses | 9.5 | | | |
EBITDA [+] | -135.8 | -515.0 | -67.9 | -13.9 |
EBITDA growth | -73.6% | 658.1% | 387.2% | |
EBITDA margin | | -8583533.3% | -17508.2% | -2047.4% |
Depreciation and amortization | 1.7 | 0.5 | 0.2 | 0.1 |
EBIT [+] | -137.5 | -515.5 | -68.1 | -14.0 |
EBIT growth | -73.3% | 657.0% | 385.5% | |
EBIT margin | | -8591600.0% | -17551.0% | -2059.5% |
Non-recurring items | -9.5 | | | |
Other income (expense), net [+] | 22.3 | 11.4 | 0.4 | 1.8 |
Change in fair value of warrants | 17.9 | 11.0 | | |
Pre-tax income | -105.7 | -504.0 | -67.7 | -12.2 |
Income taxes | 1.7 | 1.3 | 0.0 | 0.0 |
Tax rate | | | 0.0% | 0.0% |
Net income | -107.4 | -505.3 | -67.7 | -12.2 |
Net margin | | -8422166.7% | -17451.8% | -1790.7% |
|
Basic EPS [+] | ($0.37) | ($2.14) | ($0.43) | ($0.10) |
Growth | -82.9% | 393.9% | 350.8% | |
Diluted EPS [+] | ($0.37) | ($2.14) | ($0.43) | ($0.10) |
Growth | -82.9% | 393.9% | 350.8% | |
|
Shares outstanding (basic) [+] | 293.5 | 235.6 | 155.9 | 126.6 |
Growth | 24.6% | 51.1% | 23.2% | |
Shares outstanding (diluted) [+] | 293.5 | 235.6 | 155.9 | 126.6 |
Growth | 24.6% | 51.1% | 23.2% | |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|